Methicillin-resistant Staphylococcus aureus: an update

AORN J. 2010 May;91(5):599-606; quiz 607-9. doi: 10.1016/j.aorn.2009.11.065.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a serious threat to patients in health care facilities and the community. A MRSA infection can be much more severe than other bacterial infections and can be life-threatening. Resistance to common antibiotics makes treating MRSA costly and difficult. Prolonged hospitalization requiring specialized IV antibiotics also has cost implications. Treatment of MRSA can include use of antibiotics; topical therapies such as honey, topical silver, and gentian violet; and bacteriophages. Research is being conducted on new antibiotics and a MRSA vaccine.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Carrier State / microbiology
  • Carrier State / prevention & control
  • Community-Acquired Infections / microbiology
  • Cross Infection / microbiology
  • Humans
  • Methicillin-Resistant Staphylococcus aureus* / immunology
  • Methicillin-Resistant Staphylococcus aureus* / pathogenicity
  • Operating Room Nursing / methods
  • Risk Factors
  • Skin Care / methods
  • Staphylococcal Infections* / diagnosis
  • Staphylococcal Infections* / epidemiology
  • Staphylococcal Infections* / microbiology
  • Staphylococcal Infections* / therapy
  • Staphylococcal Infections* / transmission
  • Staphylococcal Vaccines

Substances

  • Anti-Bacterial Agents
  • Staphylococcal Vaccines